SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: T L Comiskey who wrote (183)3/2/2000 3:43:00 PM
From: T L Comiskey   of 370
 
Thursday March 2, 2:44 pm Eastern Time

Vion says cancer drug Phase I test completed

NEW HEAVEN, Conn., March 2 (Reuters) - Drug maker Vion Pharmaceuticals Inc. (NasdaqNM:VION - news) on Thursday said it has
completed a Phase I study of a cancer treatment.

The treatment, Triapine, works by blocking a critical step in the synthesis of DNA, preventing the replication of tumor cells.

The Phase I study was designed to assess Triapine's safety profile and pharmacokinetics when administered intravenously as a two-hour infusion every four weeks.

The study treated patients on nine dose levels of Triapine and they tolerated the treatment well, the company said, allowing further studies.

Vion said it planned to continue enrolling patients into a second Phase I trial of Triapine administered daily for five days every four weeks. Other Phase I studies are
planned, the company said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext